The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 30, 2022
Filed:
Apr. 27, 2018
University of Virginia Patent Foundation, Charlottesville, VA (US);
Universitat DE Barcelona, Barcelona, ES;
Consejo Superior DE Investigaciones Cientificas (Csic), Madrid, ES;
Thomas P. Loughran, Jr., Charlottesville, VA (US);
Gemma Fabrias, Barcelona, ES;
Jose Luis Abad, Barcelona, ES;
Josefina Casas, Barcelona, ES;
David J. Feith, Palmyra, VA (US);
Su-Fern Tan, Charlottesville, VA (US);
Jennifer M. Pearson, Charlottesville, VA (US);
Antonio Delgado Cirilo, Barcelona, ES;
University of Virginia Patent Foundation, Charlottesville, VA (US);
Universität de Barcelona, Barcelona, ES;
Consejo Superior de Investigaciones Cientificas (CSIC), Madrid, ES;
Abstract
The present application provides novel compositions and methods for treating acute myeloid leukemia (AML). Compounds of the invention are acid ceramidase inhibitors, reduce AML cell viability, inhibit AML cell proliferation, increase cell death of AML cells, and induce apoptosis in AML cells. A primary compound of the invention is SACLAC: 2-chloro-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide. The bromine analog of SACLAC (SABRAC: 2-bromo-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide) is also useful for treating AML. SACLAC has much better activity than other know drugs used to treat AML.